Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Timing your meals may lower breast cancer risk, study finds

NCT ID NCT05454943

Prevention Sponsor: University of Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether time-restricted eating (eating only during a set window each day) can lower biological and behavioral risk factors for breast cancer. It involved 178 women aged 50 or older with metabolic issues like prediabetes or type 2 diabetes. Participants followed the eating plan for 16 weeks, and researchers measured things like blood sugar control and insulin resistance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

178 people

The number who actually took part.

Started

Jul 2022

Finished

Jan 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Females * No cancer history * ≥50 years old * Have metabolic dysfunction (defined as self-reported diagnosis of pre-diabetes, type 2 diabetes, or at least moderate Canadian diabetes risk (CANRISK) score) * Access to an Ontario Lifelabs location * Owns a smartphone with Bluetooth capability with Apple or Android operating system Exclusion Criteria: * Type 1 diabetes * Taking exogenous insulin, sulfonylureas, or GLP-1 receptor agonists * Self-reported history of an eating disorder * BMI \<18.5 kg/m * Working night or rotating shifts * Eating window \<12 hours or consistently eating less than 3 meals/day in the past 3 months * Major dietary changes within the past 3 months (i.e. calorie counting, ketogenic diet)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic disturbance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic disease breast cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic disturbance

Contacts and locations

Locations

  • Remote Ontario-wide

    Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.